Alnylam Pharmaceuticals
ALNY
#618
Rank
ยฃ24.42 B
Marketcap
ยฃ188.68
Share price
3.61%
Change (1 day)
63.48%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of December 2024 : ยฃ0.97 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is ยฃ0.97 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2024-12-31ยฃ1.03 B0.79%
2023-12-31ยฃ1.02 B-6.11%
2022-12-31ยฃ1.09 B47.66%
2021-12-31ยฃ0.73 B93.28%
2020-12-31ยฃ0.38 B65.03%
2019-12-31ยฃ0.23 B880.35%
2018-12-31ยฃ23.63 M6.47%
2017-12-31ยฃ22.19 M-81.74%
2016-12-31ยฃ0.12 B
2007-12-31ยฃ3.4 M-27.07%
2006-12-31ยฃ4.66 M8.77%
2005-12-31ยฃ4.28 M14.33%
2004-12-31ยฃ3.75 M260.93%
2003-12-31ยฃ1.03 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
ยฃ0.39 B-59.47%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.02 B 108.66%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.00 B 3.63%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.37 B-61.08%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.2 M-99.98%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ23.46 B 2,311.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ13.98 B 1,337.70%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ13.56 B 1,294.93%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel